文献速递临床试验与 GCP流行病学与生物统计

抗血小板治疗对重症COVID-19患者生存及无器官支持天数的影响:一项随机临床试验

Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

在REMAP-CAP适应性平台试验中,1557例重症COVID-19成人患者随机接受阿司匹林、P2Y12抑制剂或无抗血小板治疗。抗血小板组与对照组21天内无器官支持天数中位数均为7天(校正OR 1.02,95%CrI 0.86-1.23),预设无效性标准达到后停止入组。抗血小板组出院生存率71.5% vs 对照组67.9%(校正OR 1.27,95%CrI 0.99-1.62),大出血发生率2.1% vs 0.4%(校正OR 2.97,95%CrI 1.23-8.28)。

要点

  • 抗血小板治疗未改善重症COVID-19患者21天内无器官支持天数,中位数两组均为7天。
  • 抗血小板组出院生存率71.5% vs 对照组67.9%,校正OR 1.27(95%CrI 0.99-1.62)。
  • 抗血小板组大出血发生率2.1% vs 对照组0.4%,校正OR 2.97(95%CrI 1.23-8.28)。

核心结论

  • 在重症COVID-19患者中,与不使用抗血小板药物相比,抗血小板治疗改善21天内无器官支持天数的可能性低。

研究设计与样本

  • REMAP-CAP正在进行的适应性平台试验,在多个治疗领域测试多种干预措施。
  • 2020年10月30日至2021年6月23日从8个国家105个中心纳入1557例重症COVID-19成人患者,随访90天(最终随访日期2021年7月26日)。
  • 患者随机接受开放标签阿司匹林(n=565)、P2Y12抑制剂(n=455)或无抗血小板治疗对照(n=529)。
  • 干预在医院内持续最多14天,并在抗凝血栓预防基础上加用。
  • 主要分析为贝叶斯累积逻辑模型。

主要发现

  • 抗血小板组与对照组21天内无器官支持天数中位数均为7天(IQR -1至16),校正OR 1.02(95%CrI 0.86-1.23),无效性后验概率95.7%。
  • 出院生存率抗血小板组71.5%(723/1011)vs 对照组67.9%(354/521),校正OR 1.27(95%CrI 0.99-1.62),校正绝对差5%(95%CrI -0.2%至9.5%),疗效后验概率97%。
  • 存活者中无器官支持天数中位数两组均为14天。
  • 大出血抗血小板组2.1% vs 对照组0.4%,校正OR 2.97(95%CrI 1.23-8.28),校正绝对风险增加0.8%(95%CrI 0.1%-2.7%),危害后验概率99.4%。

关键数值与推荐

  • 主要终点为21天内无器官支持天数,范围从-1(院内任何死亡,在90天删失)到22(存活且无器官支持)。
  • 疗效定义为OR大于1的后验概率大于99%。
  • 无效性定义为对比对照OR小于1.2的后验概率大于95%。
  • 干预等效性定义为两种非对照干预间OR在1/1.2至1.2之间的概率大于90%。
  • 阿司匹林组和P2Y12抑制剂组在适应性分析时达到预设等效标准,被统计合并进行进一步分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain. OBJECTIVE: To determine whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: In an ongoing adaptive platform trial (REMAP-CAP) testing multiple interventions within multiple therapeutic domains, 1557 critically ill adult patients with COVID-19 were enrolled between October 30, 2020, and June 23, 2021, from 105 sites in 8 countries and followed up for 90 days (final follow-up date: July 26, 2021). INTERVENTIONS: Patients were randomized to receive either open-label aspirin (n = 565), a P2Y12 inhibitor (n = 455), or no antiplatelet therapy (control; n = 529). Interventions were continued in the hospital for a maximum of 14 days and were in addition to anticoagulation thromboprophylaxis. MAIN OUTCOMES AND MEASURES: The primary end point was organ support-free days (days alive and free of intensive care unit-based respiratory or cardiovascular organ support) within 21 days, ranging from -1 for any death in hospital (censored at 90 days) to 22 for survivors with no organ support. There were 13 secondary outcomes, including survival to discharge and major bleeding to 14 days. The primary analysis was a bayesian cumulative logistic model. An odds ratio (OR) greater than 1 represented improved survival, more organ support-free days, or both. Efficacy was defined as greater than 99% posterior probability of an OR greater than 1. Futility was defined as greater than 95% posterior probability of an OR less than 1.2 vs control. Intervention equivalence was defined as greater than 90% probability that the OR (compared with each other) was between 1/1.2 and 1.2 for 2 noncontrol interventions. RESULTS: The aspirin and P2Y12 inhibitor groups met the predefined criteria for equivalence at an adaptive analysis and were statistically pooled for further analysis. Enrollment was discontinued after the prespecified criterion for futility was met for the pooled antiplatelet group compared with control. Among the 1557 critically ill patients randomized, 8 patients withdrew consent and 1549 completed the trial (median age, 57 years; 521 [33.6%] female). The median for organ support-free days was 7 (IQR, -1 to 16) in both the antiplatelet and control groups (median-adjusted OR, 1.02 [95% credible interval {CrI}, 0.86-1.23]; 95.7% posterior probability of futility). The proportions of patients surviving to hospital discharge were 71.5% (723/1011) and 67.9% (354/521) in the antiplatelet and control groups, respectively (median-adjusted OR, 1.27 [95% CrI, 0.99-1.62]; adjusted absolute difference, 5% [95% CrI, -0.2% to 9.5%]; 97% posterior probability of efficacy). Among survivors, the median for organ support-free days was 14 in both groups. Major bleeding occurred in 2.1% and 0.4% of patients in the antiplatelet and control groups (adjusted OR, 2.97 [95% CrI, 1.23-8.28]; adjusted absolute risk increase, 0.8% [95% CrI, 0.1%-2.7%]; 99.4% probability of harm). CONCLUSIONS AND RELEVANCE: Among critically ill patients with COVID-19, treatment with an antiplatelet agent, compared with no antiplatelet agent, had a low likelihood of providing improvement in the number of organ support-free days within 21 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02735707.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Bradbury CA, Lawler PR, Stanworth SJ, et al. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2022. PMID: 35315874. doi:10.1001/jama.2022.2910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。